Cystic Fibrosis Therapeutic Pipeline Drugs and Companies H1 2015 Review Research Report

News provided by

Mar 12, 2015, 10:00 ET

DALLAS, March 12, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Cystic Fibrosis - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the Cystic Fibrosis's therapeutic pipeline.

The report Cystic Fibrosis - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects.

Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the US and more than 35,000 cases in the European Union (EU) (Cystic Fibrosis Foundation Patient Registry, 2011; Farrell, 2008). CF causes abnormally thick, sticky mucus to accumulate in the respiratory, digestive, and reproductive systems. It is one of the most common chronic lung diseases and is widespread throughout the world. The specific defective gene that causes CF is the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete report is available @ http://www.rnrmarketresearch.com/cystic-fibrosis-pipeline-review-h1-2015-market-report.html

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include: Actelion Ltd, Alaxia SAS, AlgiPharma AS, Arcturus Therapeutics, Inc, Bayer AG, Beech Tree Labs, Inc., Carolus Therapeutics, Inc., Celsus Therapeutics Plc, Celtaxsys, Inc., Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals, Inc., Corbus pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Errant Gene Therapeutics, LLC, Galapagos NV, GlaxoSmithKline plc, Grifols, S.A., Invion Limited, InvivoGen Therapeutics, JHL Biotech, Inc., Kamada Ltd., Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc., Microbion Corporation, Mucokinetica Ltd., N30 Pharmaceuticals, NanoBio Corporation, Nostrum Pharmaceuticals, LLC, Novabiotics Ltd, Novartis AG, Ockham Biotech Limited, OSE Pharma SA, Parion Sciences, Inc., Pfizer Inc., Pharmaxis Limited, Polyphor Ltd., Progenra, Inc., ProQR Therapeutics N.V., Protalix BioTherapeutics, Inc., PTC Therapeutics, Inc., Pulmatrix, Inc., Reata Pharmaceuticals, Inc., ReveraGen BioPharma, Inc., Serendex Pharmaceuticals A/S, Shire Plc, Synovo GmbH, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Xenetic Biosciences plc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310126 (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include: (fosfomycin + tobramycin), alpha-1 proteinase inhibitor (human) second generation, ALX-009, Anti-Microbial Drug for Cystic Fibrosis, ataluren, BTL-na, CFX-1, CSY-0073, CT-2009, CTX-4430, cysteamine, D-Ivacaftor, dapsone, Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis, dornase alfa biosimilar, Drug for Cystic Fibrosis, Drug to Activate Kir 4.2 for Cystic Fibrosis, Drugs for COPD and Cystic Fibrosis, Drugs for Cystic Fibrosis Lung Infections, EBX-001, FDL-169, fenretinide, fosfomycin, Gene Therapy to Activate CFTR for Cystic Fibrosis, GLPG-1837, GSK-2225745, Heparin, JBT-101, levofloxacin, LMS-611, lumacaftor, LUNAR-CF, mannitol, miglustat, MKA-104, molgramostim, N-1785, N-1861, N-6022, N-91115, N-91138, N-91169, nadolol, NB-401, Next Generation Correctors, nitric oxide, Oligomer G for Cystic Fibrosis, Oligonucleotide to Activate CFTR for Cystic Fibrosis, ORP-100, P-1037, Peptide to Block ENaC for Cystic Fibrosis and Hypertension, POL-6014, PRX-110, pseudomonas aeruginosa vaccine, PulmoXen, PUR-118, PUR-1900, PUR-2000, PXS-4728A, QBW-251, QR-010, Recombinant A1PI, riociguat, RPL-554, Small Molecule for Cystic Fibrosis, solithromycin, SP-14, SP-9, tritoqualine, VBP-15, VRT-325.

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports of Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics

Related reports on Cystic Fibrosis:

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022

The Cystic Fibrosis EpiCast Report provides an overview of the risk factors and comorbidities associated with cystic fibrosis, as well as global trends in prevalence in the six major markets (the US, France, Germany, Italy, Spain, and the UK). It also includes a 10-year epidemiological forecast of prevalent cases of cystic fibrosis segmented by sex, age (segmented by five-year age groups, beginning at age 0 years and ending at ages 35 years and older), and mutation type (F508del, G551D, G54X, W1282X, 621+1G>1, R553X, and 3950delT).

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus:https://plus.google.com/u/0/104156468549256253075/

Twitter:https://twitter.com/RnRMR

Facebook:https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds:http://www.rnrmarketresearch.com/feed

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

SOURCE RnR Market Research